Nectar Lifesciences Limited's board of directors approved significant corporate developments during their meeting held on January 23, 2026, including business expansion plans and key appointments that mark a strategic shift for the pharmaceutical company.

Business Expansion Through New MOA

The board approved the adoption of a new set of Memorandum of Association (MOA) to expand the company's business activities beyond its current operations. The proposed amendments include three major business verticals that will diversify the company's revenue streams.

The new MOA encompasses comprehensive construction activities including departmental stores, offices, residential complexes, industrial facilities, entertainment venues, and specialized infrastructure like airports, highways, and Special Economic Zones. The company will also engage in real estate transactions involving land acquisition, development, and property management across India and international markets.

Internal Auditor Appointment

The board appointed M/s. VDR & Associates, Chartered Accountants, as the company's internal auditor for a two-year term covering financial years 2025-26 and 2026-27.

The appointed firm brings extensive experience in providing statutory audits for cooperative banks, scheduled commercial banks, and conducting stock audits, revenue audits, and internal audits for various clients.

Postal Ballot Process

Shareholders will vote on the MOA amendments through a postal ballot process, with the notice to be sent electronically to eligible members. The cut-off date for determining voting eligibility has been set as January 23, 2026, for members whose names appear in the Register of Members or List of Beneficial Owners maintained by the company and depositories.

Meeting Details

The board meeting commenced at 3:00 PM IST and concluded at 4:30 PM IST on January 23, 2026. Company Secretary and Compliance Officer Sanjaymohan Singh Rawat signed the official communication to stock exchanges, ensuring compliance with SEBI regulations.

These strategic decisions position Nectar Lifesciences for significant business diversification while maintaining regulatory compliance through proper internal audit mechanisms and shareholder approval processes.

Nectar lifesciences Limited announced its Q3FY26 financial results for the quarter ended December 31, 2025, showcasing a remarkable turnaround in profitability driven by strategic business divestments. The pharmaceutical company reported a total profit of ₹1,426.97 lacs for the quarter, marking a significant improvement from ₹784.04 lacs in the corresponding quarter of the previous year.

Financial Performance Overview

The company's financial performance for Q3FY26 demonstrates the impact of major business restructuring activities. Total income for the quarter stood at ₹66.08 lacs, comprising entirely of other income, as the company reported no revenue from operations during the period.

Major Business Divestment

The standout feature of the quarter was the completion of significant business transfers that generated substantial exceptional gains. The company successfully completed the sale of its pharmaceutical businesses to Ceph Lifesciences Private Limited through a slump sale arrangement.

The pharmaceutical business transfer included Active Pharmaceutical Ingredients business located at Unit 1 and Unit 2 in Derabassi, Punjab, and Formulation business at Unit 6 in Baddi, Himachal Pradesh. The transaction was completed on November 10, 2025, following shareholder approval on August 4, 2025.

Discontinued Operations Impact

The company's results reflect the classification of divested businesses as discontinued operations in accordance with Indian Accounting Standards. The discontinued operations, which included pharma businesses, menthol assets, and capsule business, showed varied performance across different periods.

Additional Strategic Transactions

Beyond the main pharmaceutical business sale, the company completed two additional asset transfers. The menthol business assets were sold to CEPH for ₹2,000.00 lacs, with full consideration received by December 31, 2025. Additionally, on December 20, 2025, the company entered into an agreement to sell its Empty Hard Gelatin Capsule business to Capnest Health Care Private Limited for ₹1,990.00 lacs, subject to regulatory approvals.

Earnings Per Share Analysis

The company's earnings per share metrics reflect the complex nature of its business restructuring:

Corporate Governance and Approvals

The Board of Directors reviewed and approved these financial results in their meeting held on January 23, 2026, which commenced at 3:00 PM IST and concluded at 4:30 PM IST. The Audit Committee had previously reviewed the results on the same date. Deepak Jindal & Co., Chartered Accountants, conducted the statutory limited review of both standalone and consolidated financial results.

The company also announced a share buyback program approved on December 3, 2025, involving the purchase of 3,00,00,000 equity shares at ₹27.00 per share for an aggregate amount of ₹8,100.00 lacs. The buyback payment was completed on January 13, 2026, with share extinguishment occurring on January 20, 2026.

Source: